It is estimated that seven to 10 percent of all women are affected by endometriosis, including 70 to 87 percent of women with chronic pelvic pain and 30 to 40 percent of all infertile women. Chronic pelvic pain, dysmenorrhea (painful periods) and dyspareunia (painful intercourse) are common symptoms of women with endometriosis. There are several medical treatment options, including danazol, GnRH agonists and progestins, each of which have limitations associated with patient response, tolerability, side- effect profile and duration of treatment.
"I am pleased that Meditrina will be pursing this indication, leveraging the work done to date by AstraZeneca. Anastrozole in combination with an estrogen and progestin in the area of women's gynecologic indications represents a valid medical approach and sits well with Meditrina's strategic focus and expertise," commented Dr. John Patterson, Executive Director, Research and Development, AstraZeneca.
Terms of the agreement were not disclosed.
About Meditrina Pharmaceuticals, Inc.
Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty
pharmaceutical company focused on developing and commercializing innovative
therapies that treat women's reproductive system disorders, with an initial
focus on gynecologic and aromatase-mediated conditions with serious unmet
medical needs. By identifying, leveraging and repurposing marketed products
and product candidates at advanced stages of development, Meditrina's novel
therapies have the potential to significantly alter the way these women's
health conditions are treated. For more information about Meditrina
Pharmaceuticals, please visit
|SOURCE Meditrina Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved